The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma.
 
Emily K Slotkin
Research Funding - Lilly (Inst); Lilly (Inst)
 
Audrey Mauguen
Research Funding - Amgen (Inst); ImaginAb (Inst)
Patents, Royalties, Other Intellectual Property - co-inventor of provisional patent Number 63/193,700, filed on 5/27/21; conversion deadline: 5/27/22; named “Soothsayer”, filed by Office of Technology Development, MSKCC
 
Michael Vincent Ortiz
Consulting or Advisory Role - Guidepoint Global
Research Funding - Amgen (Inst)
 
Filemon S. Dela Cruz
No Relationships to Disclose
 
Tara O'Donohue
Research Funding - Bayer (Inst); Turning Point Therapeutics (Inst)
 
Michael David Kinnaman
Consulting or Advisory Role - Cardinal Health
 
Paul A. Meyers
Honoraria - Eastern Pulmonary Conference (I); France Foundation (I)
Consulting or Advisory Role - Boehringer Ingelheim (I); Salarius Pharmaceuticals
Speakers' Bureau - France Foundation (I); Genentech/Roche (I)
Research Funding - Boehringer Ingelheim (I)
Travel, Accommodations, Expenses - InterMune (I); Takeda
 
Leonard H. Wexler
No Relationships to Disclose
 
Scarlett Rodriguez
No Relationships to Disclose
 
Viswatej Avutu
No Relationships to Disclose
 
Ciara Marie Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - ChemoCentryx; Exicure; Immunicum; Kartos Therapeutics
Research Funding - AGIOS (Inst); Amgen (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst); Servier (Inst); xencor (Inst)
 
Sandra P. D'Angelo
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier
 
Mary Louise Keohan
No Relationships to Disclose
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine; Rain Therapeutics
 
Benjamin Alexander Nacev
No Relationships to Disclose
 
Evan Rosenbaum
No Relationships to Disclose
 
Mark Andrew Dickson
Consulting or Advisory Role - Celgene
Research Funding - AADi (Inst); Lilly (Inst)
 
Katherine Anne Thornton
Consulting or Advisory Role - Epizyme; GlaxoSmithKline; More Health
 
Julia Lynne Glade Bender
Research Funding - Bayer (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on a T lympboblastic lymphoma cell line, CUTLL1
Travel, Accommodations, Expenses - Amgen (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Eisai; Merck; SpringWorks Therapeutics
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; Ayala Pharmaceuticals; Bayer; C4 Therapeutics; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; Foghorn Therapeutics; Kowa Pharmaceutical; Lilly; Medpacto; Mundipharma; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03